Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.0.1410090
European Journal of Endocrinology, Vol 141, Issue 1, 90-92
Copyright © 1999 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hamann, A
Right arrow Articles by Greten, H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hamann, A
Right arrow Articles by Greten, H

Articles

Missense variants in the human peroxisome proliferator-activated receptor-gamma2 gene in lean and obese subjects

A Hamann, H Munzberg, P Buttron, B Busing, A Hinney, H Mayer, W Siegfried, J Hebebrand, and H Greten

Medizinische Kernklinik und Poliklinik, Universitats-Krankenhaus Eppendorf, Hamburg, Germany.

The peroxisome proliferator-activated receptor-gamma2 (PPARgamma2) is almost uniquely expressed in adipose tissue and is of major importance for fat cell differentiation and lipid metabolism. This study was undertaken to assess whether two missense variants in the PPARgamma2 gene are associated with early-onset obesity. A previously described polymorphism encoding for an amino acid exchange in codon 12 (Pro12Ala) was detected with allele frequencies of 0.13 in 296 markedly obese children and adolescents and 0.14 in 130 lean individuals. A Pro115Gln variant, which had been linked to obesity in Germans in a previous association study, was not detected in any of our obese or lean subjects, who are also of German origin. We conclude from our data that these two variants in the PPARgamma2 gene are unlikely to contribute to the high prevalence of early-onset obesity.


This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
A. J. Gilde, J.-C. Fruchart, and B. Staels
Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease
J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A24 - A32.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. Orio Jr., G. Matarese, S. Di Biase, S. Palomba, D. Labella, V. Sanna, S. Savastano, F. Zullo, A. Colao, and G. Lombardi
Exon 6 and 2 Peroxisome Proliferator-Activated Receptor-{gamma} Polymorphisms in Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5887 - 5892.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
M. Bluher, G. Lubben, and R. Paschke
Analysis of the Relationship Between the Pro12Ala Variant in the PPAR-{gamma}2 Gene and the Response Rate to Therapy With Pioglitazone in Patients With Type 2 Diabetes
Diabetes Care, March 1, 2003; 26(3): 825 - 831.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 European Society of Endocrinology.